These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 16361649)

  • 1. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.
    Grothey A; Sargent D
    J Clin Oncol; 2005 Dec; 23(36):9441-2. PubMed ID: 16361649
    [No Abstract]   [Full Text] [Related]  

  • 2. [Chemotherapy of colorectal carcinoma].
    Lutz MP; Adler G
    Internist (Berl); 2001 Dec; 42(12):1567-8, 1571-6, 1578-82. PubMed ID: 11793596
    [No Abstract]   [Full Text] [Related]  

  • 3. Roles of infusional high-dose 5-fluorouracil with leucovorin in advanced colorectal cancer.
    Liu JH
    Clin Colorectal Cancer; 2004 Sep; 4(3):204-5. PubMed ID: 15377404
    [No Abstract]   [Full Text] [Related]  

  • 4. Recommendation for irinotecan, 5-fluorouracil, and leucovorin as first-line therapy for colorectal cancer.
    Fisher MD
    Clin Colorectal Cancer; 2001 Aug; 1(2):82-4. PubMed ID: 12445364
    [No Abstract]   [Full Text] [Related]  

  • 5. N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer.
    Goldberg RM
    Clin Colorectal Cancer; 2002 Aug; 2(2):81. PubMed ID: 12453321
    [No Abstract]   [Full Text] [Related]  

  • 6. Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?
    Punt CJ
    Ann Oncol; 2005 Jun; 16(6):845-6. PubMed ID: 15890668
    [No Abstract]   [Full Text] [Related]  

  • 7. [5-fluorouracil and leucovorin therapy for advanced colorectal cancer].
    Shimoyama S; Kondo K; Kataoka M
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():356-9. PubMed ID: 14574912
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
    Scartozzi M; Sobrero A; Gasparini G; Berardi R; Catalano V; Graziano F; Barni S; Zaniboni A; Beretta GD; Labianca R; Cascinu S;
    Oncology; 2005; 68(2-3):212-6. PubMed ID: 16015036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer.
    Masi G; Vasile E; Loupakis F; Bursi S; Ricci S; Petrini I; Fontana A; Allegrini G; Falcone A
    Clin Colorectal Cancer; 2008 Jan; 7(1):7-14. PubMed ID: 18279572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in colorectal chemotherapy: oral fluorinated pyrimidines, oxaliplatin and irinotecan.
    Pazdur R
    J Gastroenterol; 2000; 35 Suppl 12():131. PubMed ID: 10779234
    [No Abstract]   [Full Text] [Related]  

  • 11. Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.
    Fisher MD
    Clin Colorectal Cancer; 2001 Aug; 1(2):85-6. PubMed ID: 12445365
    [No Abstract]   [Full Text] [Related]  

  • 12. Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?
    Schmoll HJ; Sargent D
    Lancet; 2007 Jul; 370(9582):105-107. PubMed ID: 17630019
    [No Abstract]   [Full Text] [Related]  

  • 13. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
    Grothey A; Sargent D; Goldberg RM; Schmoll HJ
    J Clin Oncol; 2004 Apr; 22(7):1209-14. PubMed ID: 15051767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
    Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
    J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current perspectives in the treatment of metastatic colorectal cancer.
    Köhne CH; Folprecht G
    Ann Oncol; 2004; 15 Suppl 4():iv43-53. PubMed ID: 15477334
    [No Abstract]   [Full Text] [Related]  

  • 16. Current approaches to first-line treatment of advanced colorectal cancer.
    Goldberg RM
    Clin Colorectal Cancer; 2004 Jun; 4 Suppl 1():S9-15. PubMed ID: 15212700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer.
    Yao Y; Sun YJ; Zhao H; Guo YW; Lin F; Cai X; Tang XC; Tang LN; Zhang W
    Chin Med J (Engl); 2006 Nov; 119(21):1829-33. PubMed ID: 17097039
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomized trial comparing the addition of oxaliplatin or irinotecan to high-dose leucovorin and 5-Fluorouracil intravenous bolus every two weeks in metastatic colorectal carcinoma: Southern Italy Cooperative Oncology Group 0103.
    Comella P
    Clin Colorectal Cancer; 2003 Nov; 3(3):186-9. PubMed ID: 14706179
    [No Abstract]   [Full Text] [Related]  

  • 19. Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer.
    Wasserman E; Sutherland W; Cvitkovic E
    Clin Colorectal Cancer; 2001 Nov; 1(3):149-53. PubMed ID: 12450427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer.
    Sørbye H; Berglund A; Tveit KM; Ogreid D; Wanderås EH; Wentzel-Larsen T; Dahl O; Glimelius B
    Acta Oncol; 2007; 46(7):982-8. PubMed ID: 17917829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.